A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

In this MEDtalk, Paul Richardson MD from Dana Faber Cancer Institute, Boston, UDS, presents on behalf of his colleague Peter Voorhees the randomized phase II portion that evaluated the addition of ixazomib to pomalidomide-dexamethasone for PI naïve / sensitive patients progressing on Lenalidomide as part of 1st line therapy. The primary endpoint was progression-free survival. Critical secondary endpoints included overall response rate, depth of response, survival and safety.